Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years
Completed · Phase 1 · NCT06583031
Conditions: RSV Infection, hMPV
At a glance
- Research payments reported, 2025
- $21,000
- U.S. investigators named
- 0
- Sites paid
- 1
- Planned or actual enrollment
- 385
About the trial
- Sponsor
- Sanofi Pasteur, a Sanofi Company
- Tested
- RSV/hMPV vaccine dose A1 (biological), RSV/hMPV vaccine dose A2 (biological), RSV/hMPV vaccine dose A3 (biological), RSV/hMPV vaccine dose B1 (biological), RSV/hMPV vaccine dose B2 (biological), RSV/hMPV vaccine dose B3 (biological), RSV/hMPV vaccine dose C1 (biological), RSV/hMPV vaccine dose C2 (biological), RSV/hMPV vaccine dose C3 (biological), RSV/hMPV vaccine dose 1 (biological), RSV/hMPV vaccine dose 2 (biological), RSV/hMPV vaccine dose 3 (biological), Monovalent RSV Vaccine (biological)
- Dates
- Started 2024-10-09; completion 2025-10-09
- Results posted
- Not yet
VAV00039 is a first-in-human (FiH) study to assess the safety and immunogenicity (in adult participants aged 60-75 years) after a single injection of different dose formulations of an RSV/hMPV vaccine candidate and RSV vaccine.
From ClinicalTrials.gov, last updated 2025-11-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi Pasteur Inc. reported $21,000 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.